Olmesartan Medoxomil + Hydrochlorothiazide

Olmesartan/hydrochlorothiazide is a single-pill, fixed-dose combination of two long-established antihypertensive medicines ^[1][3]. One component, olmesartan medoxomil, is an angiotensin II receptor blocker (ARB) that relaxes blood vessels by interrupting the renin-angiotensin-aldosterone system; the other, hydrochlorothiazide, is a thiazide diuretic that lowers blood volume by increasing the kidneys' excretion of salt and water. Combining an ARB with a thiazide is one of the most common and best-studied approaches to hypertension that does not respond to a single drug ^[1].

The two agents complement each other in more than one way. Beyond their additive effect on blood pressure, the diuretic tends to activate the renin-angiotensin system, an effect that olmesartan blunts, while olmesartan in turn helps limit the drop in potassium that thiazides can produce ^[1]. Olmesartan is supplied as a medoxomil prodrug that is converted to its active form after absorption, and the combination product is made in several fixed strength ratios so treatment can be adjusted ^[3].

The combination is indicated for essential hypertension, usually as a second step for patients not at goal on a single drug, and in some cases as initial therapy for those who need a large reduction in pressure ^[1][3]. Clinical trials show that adding hydrochlorothiazide to olmesartan, or olmesartan to hydrochlorothiazide, lowers blood pressure more than either drug alone and helps a large majority of patients reach recommended targets, over both the short and long term ^[1]. A meta-analysis of individual patient data found that, when paired with olmesartan, hydrochlorothiazide lowered 24-hour ambulatory blood pressure about as effectively as the calcium channel blocker amlodipine, although the amlodipine pairing produced somewhat greater reductions in clinic-measured pressure ^[2].

The fixed-dose olmesartan/hydrochlorothiazide tablet is a prescription-only medicine, sold as Benicar HCT in the United States and under names such as Olmetec Plus elsewhere, and it is available as a generic ^[1]. Because it contains a renin-angiotensin blocker, it carries the class warning against use in pregnancy, and the thiazide component calls for periodic monitoring of electrolytes and kidney function ^[1][2].

This is a prescription combination. Common effects include dizziness, headache, and the metabolic shifts of a thiazide such as low potassium or sodium, higher uric acid or blood sugar, and photosensitivity; the angiotensin blocker can instead push potassium up, so the net balance is watched with blood tests. It must not be used in pregnancy because drugs acting on the renin-angiotensin system can injure or kill a developing fetus. Olmesartan has a rare but well documented link to a sprue-like enteropathy with severe chronic diarrhea and weight loss that resolves after stopping. Use caution with other potassium-raising drugs, lithium, and NSAIDs, and in significant kidney disease or a sulfonamide allergy; avoid pairing with aliskiren in people with diabetes.

This combination carries the interaction profile of both components, and they do not always point the same way.

From olmesartan: pairing it with an ACE inhibitor or with aliskiren produces dual renin-angiotensin blockade, which raises rates of hyperkalemia, hypotension and acute kidney injury without improving outcomes; the aliskiren pairing is contraindicated in diabetes. Potassium supplements and potassium-sparing diuretics add to the potassium-retaining effect. Colesevelam binds olmesartan in the gut and lowers its exposure.

From hydrochlorothiazide: lithium clearance falls when a thiazide is added, and lithium toxicity has followed. Thiazide-induced hypokalemia and hypomagnesemia potentiate digoxin toxicity and the QT effects of other drugs.

NSAIDs interact with both halves at once, blunting the antihypertensive effect and, in volume-depleted or elderly patients, precipitating acute kidney injury through the well-described combination of an NSAID, a diuretic and a renin-angiotensin blocker.

Checking a whole stack? Run it through interactions + stacks.

This fixed-dose tablet combines a modern angiotensin II receptor blocker with one of the oldest and most widely used diuretics. Hydrochlorothiazide was developed in the late 1950s and became a cornerstone of hypertension therapy for decades, while olmesartan medoxomil was introduced by Sankyo, now Daiichi Sankyo, in 2002. Following a long tradition of pairing an ARB or ACE inhibitor with a thiazide, Daiichi Sankyo brought the combination to market in 2003, roughly a year after olmesartan itself, under brand names such as Benicar HCT in the United States and Olmetec Plus in other regions.

The pairing was designed for patients whose blood pressure remained above goal on olmesartan or a diuretic alone, offering additive control in a single daily tablet. The two drugs were chosen in part because their mechanisms are complementary in a self-reinforcing way, with the receptor blocker counteracting the compensatory hormonal responses that a diuretic tends to switch on. It became a standard step-up option in hypertension management worldwide.

The olmesartan-hydrochlorothiazide tablet is a long-established, dependable step-up therapy whose two ingredients are known quantities backed by decades of clinical experience. Its appeal lies in genuine mechanistic synergy: the diuretic lowers blood volume, and because that maneuver would normally activate the renin-angiotensin system, olmesartan's blockade of that system keeps the counter-response from undoing the benefit, so together they lower pressure more than either does alone.

A further advantage is that olmesartan's mild potassium-sparing effect partially offsets the potassium loss thiazides can cause, easing one of the diuretic's classic drawbacks. Balanced against this, hydrochlorothiazide can raise blood sugar, uric acid, and lipids modestly and may cause photosensitivity, so it is not ideal for every patient, and the fixed doses allow less individual titration. For the many patients who need two agents, however, it remains a convenient, well-validated, and cost-effective choice.